RCT: Clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention (WOEST)
Source: Lancet
Area: News
If percutaneous coronary intervention (PCI) is required in patients taking oral anticoagulants, double antiplatelet therapy with aspirin and clopidogrel is indicated. However, such triple therapy increases the risk of serious bleeding and this treatment strategy has not been tested prospectively.
Omission of oral anticoagulants could lead to an increased risk of thrombotic stroke, whereas clopidogrel is essential to prevent stent thrombosis. The exclusion of aspirin might, therefore, be useful to reduce the bleeding risk in patients with coronary artery disease.
The open-l...
Source: NeLM - News - February 13, 2013 Category: Drugs & Pharmacology Source Type: news
Short course of aspirin, clopidogrel cuts stroke risk
Brief combination therapy reduces recurrent stroke over aspirin alone, without increasing bleeding risk, CHANCE trial results show. (Source: theHeart.org)
Source: theHeart.org - February 12, 2013 Category: Cardiology Source Type: news
Adding Clopidogrel to Aspirin Therapy Reduces Risk of Second Stroke
Source: American Heart Association
Related MedlinePlus Pages: Blood Thinners, Stroke (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - February 12, 2013 Category: Consumer Health News Source Type: news
Short Course of Aspirin, Clopidogrel Cuts Stroke RiskShort Course of Aspirin, Clopidogrel Cuts Stroke Risk
Brief combination therapy reduces recurrent stroke over aspirin alone, without increasing bleeding risk, CHANCE trial results show. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 11, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Antiplatelet Duo Helps After Minor Stroke (CME/CE)
HONOLULU (MedPage Today) -- In the months immediately after a minor stroke or transient ischemic attack (TIA), adding clopidogrel to aspirin therapy cuts the risk of another stroke, a Chinese trial showed. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 10, 2013 Category: Cardiology Source Type: news
Sanofi CEO: It's Not A Plavix Hangover, We're Investing In Launching New Drugs
Sanofi, which has been one of the best-performing drug stocks over the past year, is getting hit today because the company said that earnings in 2013 will be somewhere between flat and down 5%. That's a big deal because Sanofi had previously said that 2013 would be a "trough year," the low point before it returns to growth after facing patent expirations for Plavix, once one of the biggest selling medicines in the world, and other drugs. The company reiterated its guidance out to 2015, despite pointed questions from analysts, but the stock is still trading down almost 6% on the New York Stock Exchange. (Source: Forbes...
Source: Forbes.com Healthcare News - February 7, 2013 Category: Pharmaceuticals Authors: Matthew Herper Source Type: news
Science minister lobbies health department over ticagrelor
Source: BMJ
Area: News
According to a report in the British Medical Journal (BMJ), Government ministers are stepping up efforts to boost NHS prescriptions of recommended new drugs made by companies with a significant presence in the United Kingdom. This follows growing complaints from the drug industry that doctors are not prescribing drugs which have been recommended by NICE.
The example of ticagrelor is highlighted - this has been approved by NICE as a treatment option for adults with acute coronary syndromes but is more costly than clopidogrel (£54.60 versus £3.40 per month). AstraZeneca say that only 42% ...
Source: NeLM - Cardiovascular Medicine - February 4, 2013 Category: Cardiology Source Type: news
Outsource Or Manage Internally? Pharma Logistics, 9-10 April 2013, Vienna, Austria
"The current trend in pharma logistics is the shift from blockbuster drugs. 6 out of 10 top selling drugs will lose their patents in one year, so there will be increase in the use of generic drugs," Sebastiaan Scholte, Chairman at Cool Chain Association, pointed out when speaking about the latest developments. These trends influence drug manufacturers and make them rethink their strategies. Already without medications like Lipitor and Plavix bolstering their bottom lines, manufacturers have to cut costs in order to stay competitive... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 31, 2013 Category: Consumer Health News Tags: Conferences Source Type: news
Tax Benefit Boosts Bristol's Profit
Bristol-Myers Squibb's fourth-quarter profit rose 8.6% on a tax benefit, while sales tumbled 23% due to generic competition for the company's former top product, the anti-clotting drug Plavix. (Source: WSJ.com: Health)
Source: WSJ.com: Health - January 24, 2013 Category: Pharmaceuticals Tags: PAID Source Type: news
Pharmacodynamics of Prasugrel vs Clopidogrel in ElderlyPharmacodynamics of Prasugrel vs Clopidogrel in Elderly
Which therapy is best for elderly patients presenting with acute coronary syndromes? American Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 23, 2013 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Blue Sky Drugs Announces Holiday Promotion on Newest Blood Thinners
Blue Sky Drugs is offering a holiday promotion on the newest blood thinner medications. Anticoagulants protect against the formation of clots.(PRWeb January 17, 2013)Read the full story at http://www.prweb.com/releases/canadianpharmacy/plavix/prweb10313064.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 18, 2013 Category: Pharmaceuticals Source Type: news
Hospital case volume and appropriate prescriptions at hospital discharge after acute myocardial infarction: a nationwide assessment
Source: Circulation: Cardiovascular Quality and Outcomes
Area: Evidence > Medicines Management > References
Background: In acute myocardial infarction, the relationship between volume and quality indicators (QIs) is poorly documented. Through a nationwide assessment of QIs at discharge repeated for 3 years, we aimed to quantify the relationship between volume and QIs in survivors after acute myocardial infarction.
Methods and Results: Almost all healthcare centres in France participated. Medical records were randomly selected. Data collection was performed by an independent group. QIs fo...
Source: NeLM - Cardiovascular Medicine - January 17, 2013 Category: Cardiology Source Type: news
Abuse of Opana ER (oxymorphone) associated with thrombotic thrombocytopenic purpura
3.5 out of 5 stars
Thrombotic Thrombocytopenic Purpura (TTP)-Like Illness Associated with Intravenous Opana ER Abuse — Tennessee, 2012. MMWR 2013 Jan 11;62:1-4.
Full Text
This paper describes a 2012 CDC investigation into a cluster of 15 cases of thrombotic thrombocytopenic purpura (TTP)-like illness in the state of Tennessee. TTP-like illness was defined as microangiopathic hemolytic anemia (hemolytic anemia anemia based on haptoglobin and lactate dehydrogenase with schistocytes and an admission platelet count < 50,000/μL. Typical TTP-like signs and symptoms included nausea (11 patients), abdominal pain (11), f...
Source: The Poison Review - January 15, 2013 Category: Toxicology Authors: Leon Tags: Medical opana oxymorphone thrombotic thrombocytopenic purpura ttp Source Type: news
Analysis of recurrent events in patients receiving ticagrelor or clopidogrel for ACS in the PLATO study
Source: Circulation
Area: News
According to an analysis of recurrent events in the PLATO study, ticagrelor reduces both the first and recurrent cardiovascular events in patients with acute coronary syndrome (ACS) compared with clopidogrel. Although it is associated with a slightly increased risk of having a first non-CABG major bleed, the bleeding risk appears to be similar to clopidogrel thereafter.
The authors note that censoring patients after the first occurrence of any primary endpoint event in clinical trials limits the information available on the effect of therapy on subsequent events, and leaves...
Source: NeLM - Cardiovascular Medicine - January 14, 2013 Category: Cardiology Source Type: news
Research suggests optimal duration of dual antiplatelet therapy may vary depending on stent type
Source: Eur Heart J
Area: News
According to research published early online in the European Heart Journal, the optimal duration of dual antiplatelet therapy (DAPT) may differ depending on the type of stent implanted.
The authors note that this currently remains a controversial issue due to the lack of prospective, randomised data. They conducted a pre-specified analysis of the PRODIGY study to assess device-specific outcomes relative to different duration of DAPT after everolimus- (EES), paclitaxel (PES), zotarolimus- (ZES-S) eluting, or bare metal stent (BMS) insertion.
The open-label PRODIGY ...
Source: NeLM - Cardiovascular Medicine - January 14, 2013 Category: Cardiology Source Type: news
